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IMPORTANCE Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density
lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that
the clinical benefit of lowering LDL-Cmay depend on how LDL-C is lowered.
OBJECTIVE To estimate the association between changes in levels of LDL-C (and other
lipoproteins) and the risk of cardiovascular events related to variants in the CETP gene, both
alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) gene.
DESIGN, SETTING, AND PARTICIPANTS Mendelian randomization analyses evaluating the
association between CETP andHMGCR scores, changes in lipid and lipoprotein levels, and the
risk of cardiovascular events involving 102 837 participants from 14 cohort or case-control
studies conducted in North America or the United Kingdom between 1948 and 2012. The
associations with cardiovascular events were externally validated in 189 539 participants
from 48 studies conducted between 2011 and 2015.
EXPOSURES Differences inmean high-density lipoprotein cholesterol (HDL-C), LDL-C, and
apolipoprotein B (apoB) levels in participantswithCETP scores at or above vs below themedian.
MAIN OUTCOMES ANDMEASURES Odds ratio (OR) formajor cardiovascular events.
RESULTS The primary analysis included 102 837 participants (mean age, 59.9 years; 58%
women) who experienced 13 821 major cardiovascular events. The validation analyses
included 189 539 participants (mean age, 58.5 years; 39%women) with 62 240 cases of
coronary heart disease (CHD). Considered alone, the CETP score was associated with higher
levels of HDL-C, lower LDL-C, concordantly lower apoB, and a corresponding lower risk of
major vascular events (OR, 0.946 [95% CI, 0.921-0.972]) that was similar in magnitude to the
association between theHMGCR score and risk of major cardiovascular events per unit
change in levels of LDL-C (and apoB). When combined with theHMGCR score, the CETP score
was associated with the same reduction in LDL-C levels but an attenuated reduction in apoB
levels and a corresponding attenuated nonsignificant risk of major cardiovascular events
(OR, 0.985 [95% CI, 0.955-1.015]). In external validation analyses, a genetic score consisting
of variants with naturally occurring discordance between levels of LDL-C and apoBwas
associated with a similar risk of CHD per unit change in apoB level (OR, 0.782 [95% CI,
0.720-0.845] vs 0.793 [95% CI, 0.774-0.812]; P = .79 for difference), but a significantly
attenuated risk of CHD per unit change in LDL-C level (OR, 0.916 [95% CI, 0.890-0.943] vs
0.831 [95% CI, 0.816-0.847]; P < .001) compared with a genetic score associated with
concordant changes in levels of LDL-C and apoB.
CONCLUSIONS AND RELEVANCE Combined exposure to variants in the genes that encode the
targets of CETP inhibitors and statins was associated with discordant reductions in LDL-C and
apoB levels and a corresponding risk of cardiovascular events that was proportional to the
attenuated reduction in apoB but significantly less than expected per unit change in LDL-C.
The clinical benefit of lowering LDL-C levels may therefore depend on the corresponding
reduction in apoB-containing lipoprotein particles.
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M endelianrandomizationstudiesandrandomizedtrialsof various lipid-lowering therapies have consis-tentlydemonstrated that lower levels of low-density
lipoproteincholesterol (LDL-C)maybecausallyassociatedwith
a lower risk of cardiovascular disease.1-4 Together, these stud-
ies suggest that lowering LDL-C levels should reduce the risk
of cardiovascular events proportional to the absolute reduc-
tion inLDL-C, largely independentof themechanismbywhich
LDL-C is lowered.5
The notable exception to this observation is the class of
drugs known as cholesteryl ester transfer protein (CETP)
inhibitors.4 Although CETP inhibitors were originally de-
signed to increase levels of high-density lipoprotein choles-
terol (HDL-C),6 themore potent CETP inhibitors also robustly
lower levels of LDL-C.7-11 However, in the ACCELERATE trial,
treatmentwith theCETP inhibitor evacetrapib reducedLDL-C
levels by 29mg/dL (0.75 mmol/L) but did not reduce the risk
of cardiovascular events.11 This result has created uncer-
tainty about the causal effect of LDL-C on the risk of cardio-
vasculardisease and raises thepossibility that the clinical ben-
efit of lowering LDL-Cmay depend on howLDL-C is lowered.
In this study, amendelian randomizationanalysiswascon-
ductedtoevaluatetheassociationbetweenlowerlevelsofLDL-C
(andothermeasures of lipoprotein concentration) and the risk
of cardiovascular events due to variants in the gene that en-
codes the target of CETP inhibitors and compare it to the asso-
ciation between lower LDL-C levels and the risk of cardiovas-
culareventsdue tovariants in thegenes thatencode the targets
of statins, ezetimibe, and proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors to make inferences about
whether the clinical benefit of lowering LDL-C might depend
on how LDL-C is lowered. Because the cardiovascular out-
come trials have evaluated the effect of treatmentwith aCETP
inhibitor on the background of statin therapy, the associations
of the CETP variants were evaluated both alone and in combi-
nation with variants of the 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR) gene, which encodes the target of statins.
Methods
Study Design
The study consisted of 3 sequential parts as summarized in
Figure 1. First, a mendelian randomization study was con-
ducted tomeasure the association between lipid changes due
to a genetic score consisting of variants in the CETP gene and
the risk of cardiovascular events. Themagnitude of the asso-
ciationbetween theCETP genetic score and the risk of cardio-
vascular eventswas then comparedwithmagnitudeof the as-
sociationbetweenthe riskof cardiovasculareventsandgenetic
scores consisting of variants in theHMGCR gene (NCBI Entrez
Gene 3156, which encodes for the target of statins), the
Niemann-Pick C1-Like 1 intracellular cholesterol transporter
1(NPC1L1) gene (NCBI Entrez Gene 29881, which encodes for
the targetofezetimibe), andthePCSK9gene (NCBIEntrezGene
255738,which encodes for the target of PCSK9 inhibitors), re-
spectively. The objective of this analysis was to make infer-
ences about whether lower LDL-C levels due to CETP inhibi-
tion has the same causal effect on the risk of cardiovascular
events as other methods of lowering LDL-C levels.12
Second, a 2 × 2 factorial mendelian randomization study
was conducted to measure the association between lipid
changes due to combined exposure to the CETP and HMGCR
genetic scores and the risk of cardiovascular events. Themag-
nitude of these associations were then compared with the
magnitude of the associations with the CETP score alone.
The objective of this analysis was to make inferences about
whether the effect of CETP inhibitionon lipid changes and the
risk of cardiovascular events is modified by inhibition of
3-hydroxy-3-methylglutaryl-CoA reductase.
Third, a mendelian randomization study was conducted
tomeasure the associationbetween the risk of coronaryheart
disease and a score consisting of genetic variants associated
with discordant changes in levels of LDL-C and apolipopro-
tein B (apoB). Themagnitude of the association between this
discordant variant genetic score and the risk of cardiovascu-
lar events was then compared with the magnitude of the as-
sociation between a genetic score consisting of variants asso-
ciated with concordant changes in levels of LDL-C and apoB
and the risk of cardiovascular events,measured both per unit
change inLDL-Candperunit change inapoB, respectively.The
objectiveof thisanalysiswas tomake inferencesaboutwhether
the causal effect of LDL on the risk of cardiovascular events is
determined by the cholesterol mass carried by LDL particles
(as measured by LDL-C level) or by the concentration of cir-
culating LDL particles (as estimated by apoB level) and there-
fore tomake further inferencesaboutwhether theclinical ben-
efit of lowering LDL-C levelmay depend onhow it is lowered.
Study Population
Theprimaryanalyses includedindividual-participantdata from
all studies in the National Center for Biotechnology Informa-
tion database of Genotypes and Phenotypes program that re-
ported data on cardiovascular outcomes.13 These 14 cohort or
case-control studies includeda total of 112 772participants.Of
these, 102837 participants had adequate genetic information
for all variants included in the various genetic scores investi-
gated in this study andwere included in the analysis without
Key Points
Question Does the clinical benefit of lowering low-density
lipoprotein cholesterol (LDL-C) levels depend on how LDL-C
is lowered?
Findings In a mendelian randomization analysis of an
individual-participant data meta-analysis that included 102 837
participants, combined exposure to variants related to the action
of CETP inhibitors and statins was significantly associated with
discordant reductions in LDL-C and apolipoprotein B levels;
the corresponding association with cardiovascular events was
proportional to the attenuated reduction in apolipoprotein B
but less than expected per unit change in LDL-C.
Meaning The clinical benefit of lowering LDL-Cmay be related
to the corresponding absolute reduction in apolipoprotein
B-containing lipoprotein particles and therefore may depend
on how LDL-C is lowered.
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restrictions or exclusions. All racial/ethnic groups for which
data were reported were included in the analysis. In each co-
hort or case-control study, race/ethnicity was self-identified
usinga study-specific fixed-categoryquestionnaire.Adescrip-
tionof the includedstudiesand thegenotypingplatformsused
in each study is provided in eTable 1 in the Supplement.
External replicationandvalidationanalyses includedsum-
mary-level data froma total of up to 189539participants from
48 studies as part of the Coronary Artery Disease Genome-
WideReplication andMeta-analysis plus theCoronaryArtery
Disease Genetics Consortium (CARDIOGRAMplusC4D).14,15
Contributing studies received ethical approval from their re-
spective institutional reviewboards,andwritten informedcon-
sent was obtained from all participants. Analysis of the indi-
vidual-participant data was approved by the Wayne State
University institutional review board.
Study Outcomes
Theprimaryoutcomefor the individualparticipantdataanaly-
ses was major cardiovascular events, defined as a composite
of the first occurrence of myocardial infarction, coronary re-
vascularization, stroke, or coronary death. The primary out-
come for analyses using summary-level data was coronary
heart disease (CHD), as definedby theCARDIoGRAMplusC4D
Consortium.14,15
Genetic Instruments
TheCETPgenetic scorewas constructedbycombiningall vari-
ants within 100kb on either side of the CETP gene that were
conditionally associatedwithHDL-C levels (themajor lipid ef-
fect of CETP inhibition) at a genome-wide level of signifi-
cance (P < 5 × 10−8) and that were in low linkage disequilib-
rium(r2<0.4)withallothervariants included inthescore,using
a forward stepwise conditional regression procedure among
participants free fromcardiovasculardiseaseatbaseline ineach
study (eFigure 1 in the Supplement). The exposure allele for
each variant was defined as the allele associated with higher
HDL-C levels.16
Foreachparticipantwith individualdata, aweightedCETP
genetic score was calculated by summing the number of
HDL-C–raising alleles that each participant inherited at each
variant included in the score,weighted by each variant’s con-
ditional effect onHDL-C levelsmeasured inmg/dL. For analy-
ses involving summary-level data, genetic scores were calcu-
latedusing theusual ratio of effect estimatesmethod.Genetic
scores forHMGCR,NPC1L1, andPCSK9wereconstructedusing
a similar procedure, as previously described.17,18
Allocation of Exposures
In individual-participant analyses, theCETPgenetic scorewas
dichotomized and used as an instrument to allocate partici-
pants into 2 approximately equal-sized groups based on
whether theirCETP scorewas either equal to or above theme-
dian or below the median (eFigure 2 in the Supplement). To
evaluatedoseresponse,participantsweredivided into4groups
based on the quartile value of their CETP score.
To conduct the 2 × 2 factorial mendelian randomization
analysis, participants were first allocated into 2 groups based
onwhether theirHMGCR genetic score was equal to or above
themedianorbelowthemedian;participants ineitherof these
2 groups were then allocated into 2 further groups based on
whether theirCETPgenetic scorewasequal toorabove theme-
dian or below the median (eFigure 2 in the Supplement).17,18
To conduct the stratified analysis, participants were first di-
vided into 2 groups basedonwhether theirHMGCR scorewas
equal to or above themedianor below themedian, and the as-
sociations of the CETP score with cardiovascular events was
then evaluated as a continuous variable (without dichotomi-
zation to increase statistical power to detect effect modifica-
tion) in each of these 2 groups separately.
Figure 1. Study Design
Analysis
Mendelian randomization study evaluating
association between CETP variants, changes
in lipid and lipoprotein levels, and risk of
cardiovascular events
Objectives
To compare the causal effect of lower LDL-C
and apoB levels on risk of cardiovascular
events due to variants in genes that encode
targets of CETP inhibitors, statins, ezetimibe,
and PCSK9 inhibitors
Data Sources
Primary Analysis
Individual-participant data from 14 cohort
or case-control studies13 (N = 102 837)
Replication Analysis
Summary data from CARDIoGRAMplusC4D
(n = 189 539)
Mendelian randomization study comparing the
association between variants with discordant
changes in LDL-C and apoB levels and risk of
cardiovascular events with the association
between variants with concordant changes
in LDL-C and apoB levels and risk of
cardiovascular events
To determine if the causal effect of LDL on
risk of cardiovascular events is determined
by the cholesterol mass carried by LDL
particles (estimated by LDL-C level) or by
the concentration of circulating LDL particles
(estimated by apoB level)
External Validation Analysis
Summary data from CARDIoGRAMplusC4D
(n = 184 305)
2 × 2 Factorial mendelian randomization
study evaluating association between
combined exposure to CETP and HMGCR
variants, changes in lipid and lipoprotein
levels, and risk of cardiovascular events
To investigate whether the effect of CETP
inhibition on changes in lipid and lipoprotein
levels and risk of cardiovascular events is
modified by HMGCR inhibition
Primary Analysis
Individual-participant data from 14 cohort
or case-control studies13 (N = 102 837)
CARDIoGRAMplusC4D indicates Coronary Artery Disease Genome
Wide Replication andMeta-analysis plus the Coronary Artery Disease
Genetics Consortium; CETP, cholesteryl ester transfer protein;
HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; LDL-C, low-density
lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9.
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Statistical Analysis
For analyses involving individual-participant data, the abso-
lute difference in mean levels of various biomarkers between
groupswasmeasured using linear regression, and the associa-
tionwith the riskof cardiovascular eventswasmeasuredusing
logistic regression. All analyseswere adjusted for age, sex, and
the first 5principal componentsofancestry.Analyseswereper-
formed separately in each included study.Mendelian random-
izationestimateswere thenobtainedbycombining these sum-
marized associations using a previously reportedmethod that
accounts for correlation between variants.19
Foranalyses involvingsummary-leveldata, theassociation
between a genetic score and the risk of CHDwas calculated by
looking up the effect estimate of each variant included in that
scoreontheriskofCHDasreportedbytheCARDIoGRAMplusC4D
Consortium,dividingthateffectsize(andcorrespondingstandard
error) by the effect estimate of that variant on levels of HDL-C,
LDL-C,orapoB(dependingontheanalysis)andthencombining
theadjustedeffectestimatesforallvariants includedinthatscore
inaninverse-variance-weightedfixed-effectsmeta-analysis.Plei-
otropywas assessed usingMR-Egger regression.20
To identify variants associatedwith discordant changes in
levelsofLDL-CandapoB,agenome-wideassociationstudywas
conductedamong65829participants from15studies inEurope
andtheUnitedKingdom,allofwhomhadLDL-CandapoBmea-
surements performed on the same nuclear magnetic reso-
nancemetabolomicplatform(eTable2 in theSupplement).21,22
DiscordantvariantsweredefinedasbeingassociatedwithLDL-C
atP < 5 × 10−4andwithat least a2-foldgreater change inLDL-C
level as comparedwith apoB, measured inmg/dL.
The threshold of statistical significance for the association
between each genetic score and all outcomes or biomarker dif-
ferenceswasP < .05(2-sided).Allanalyseswereperformedusing
STATA 14, R version 3.2.5 (R Project for Statistical Computing),
orGoldenHelixSNP&VariationSuite (version8.1.4).Adetailed
description of themethods is provided in the Supplement.
Results
Theweightedmean age of the 102837 study participantswas
59.9 years. Theweightedmean level of high-density lipopro-
teincholesterol (HDL-C)was52.0mg/dL;ofLDL-C, 129.7mg/dL
(to convert lipid values to mmol/L, multiply by 0.0259); and
of apoB, 101.4mg/dL (eTable 3 in the Supplement). Studypar-
ticipants experienced a total of 13 821 firstmajor cardiovascu-
lar events. The stepwise selection procedure identified 8 ge-
netic variants conditionally associated with HDL-C level that
were included in the CETP genetic score; 6 variants were in-
cluded in the HMGCR genetic score as previously reported
(eTables 4-7 in the Supplement).17,18 There were no differ-
ences in any nonlipid baseline characteristics between the
groupsbeing compared, thusdemonstrating that allocation to
each group appeared to be random (Table 1). The distribution
of genetic scores for each group being compared in all analy-
ses is presented in eTable 8 in the Supplement.
Table 1. Baseline Characteristics of 102 837 Participants From 14 Cohort or Case-Control Studies by CETPGenetic Scorea
Characteristic
Mean (95% CI)
P ValueCETP Score <Median (n = 49 435) CETP Score ≥Median (n = 53 402)
Age, y 59.8 (59.7-59.9) 60.0 (59.9-60.1) .13
Women, % 58.3 58.2 .87
Blood pressure, mm Hg
Systolic 127.3 (127.1-127.5) 127.5 (127.3-127.7) .11
Diastolic 75.0 (74.9-75.1) 74.9 (74.8-75.0) .16
Weight, kg 76.9 (76.7-77.1) 76.8 (76.6-77.0) .48
Body mass indexc 27.7 (27.6-27.8) 27.6 (27.5-27.7) .19
Prevalent diabetes at baseline, No. (%) 4.2 4.1 .57
Ever smoker, No. (%) 54.4 54.3 .65
Lipid levels, mg/dL
LDL-C 130.8 (130.3-131.3) 128.7 (128.2-129.2) <.001
apoB 102.1 (101.5-102.7) 100.7 (100.1-101.3) .004
HDL-C 49.6 (49.4-49.8) 54.4 (54.2-54.6) <.001
Triglycerides 119.7 (81-159) 115.2 (77-156) <.001
Total cholesterol 205.7 (205.3-206.1) 207.5 (207.1-207.9) <.001
Non–HDL-Cb 155.1 (154.7-155.5) 151.9 (151.5-152.3) <.001
Abbreviations: apoB, apolipoprotein B; CETP, cholesteryl ester transfer protein;
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range;
LDL-C, low-density lipoprotein cholesterol.
SI conversion factors: To convert HDL-C, LDL-C, and non–HDL-C values to
mmol/L, multiply by 0.0259.
a Values in the table represent weightedmean values of the baseline
characteristics for the entire study sample (age and sex) or from the cohort
studies (for all other variables) in either group, after combining study-specific
estimates in an inverse variance–weightedmeta-analysis of the
individual-participant data from up to 102 837 participants enrolled in one of
14 cohort or case-control studies. Among all participants, median CETP score
was 34.8 (IQR, 28.3-41.1; range, 0-54.3). For participants in the group with
CETP scores below themedian, median CETP score was 28.2 (IQR, 23.3-32.0;
range, 0-34.7). For participants in the group with CETP scores equal to or
above themedian, median CETP score was 41.1 (IQR, 37.9-44.8; range,
34.8-54.3). Higher scores indicate a greater number of HDL-C–raising alleles
(weighted by the effect of each allele on HDL-C level).
b Calculated as the difference between total cholesterol and high-density
lipoprotein cholesterol levels.
c Calculated as weight in kilograms divided by height in meters squared.
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Overall, as compared with participants with CETP scores
below the median, participants with CETP scores equal to or
above the median had lower mean CETP activity resulting in
4.62mg/dLhighermeanHDL-C level, 2.15mg/dL lowermean
LDL-C, 1.39 mg/dL lower mean apoB, and a corresponding
lower risk of major cardiovascular events (odds ratio [OR],
0.964 [95%CI,0.955-0.983];P < .001). Indose responseanaly-
ses, increasingquartilesof theCETP scorewereassociatedwith
a step-wise increase in mean HDL-C, step-wise decreases in
mean LDL-C and apoB, and a corresponding step-wise de-
crease in the risk of major cardiovascular events (Figure 2A).
Instandardizedanalyses,theCETPscorewasassociatedwith
a very similar risk ofmajor cardiovascular events per 10-mg/dL
lower LDL-C level (and per 10-mg/dL lower apoB) as compared
with theHMGCR,NPC1L1, andPCSK9genetic scores (Figure2B
and C).
Inexternal replicationanalyses involvingup to62240par-
ticipants with CHD and 127 299 control participants from the
CARDIoGRAMplusC4DConsortium, theCETP scorewas asso-
ciated with a lower risk of CHD (OR, 0.968 [95% CI, 0.956-
0.981]; P < .001). This association was very similar in magni-
tude compared with the association between the HMGCR,
NPC1L1, andPCSK9genetic scores and the riskofCHDperunit
change in LDL-C level (and per unit change in apoB) (eFigure
3 in the Supplement).
In the 2 × 2 factorial analysis, compared with participants
with bothCETP andHMGCR scores below themedian, partici-
pants in the groupwith bothCETP andHMGCR scores equal to
or above themedian had additively highermeanHDL-C levels
and additively lower mean LDL-C (Table 2). However, partici-
pants in thisgrouphadanattenuated less thanadditively lower
change inmean apoB, with no further significant reduction in
Figure 2. Association of CETP ScoreWith Risk ofMajor Cardiovascular Events Among 102837 Participants From 14 Cohort or Case-Control Studies
Main effects and dose responseA
0.7 2.01.0
OR (95% CI)
Major Cardiovascular
Events, No. of Cases/
No. of Participants (%)
Change, Mean (95% CI), mg/dL 
HDL−C LDL−C apoBGroup
Primary analysis
OR (95% CI)
CETP score
7048/53 402 (13.2) 4.62 (3.84-5.40) –1.47 (–2.54 to –0.40)–2.15 (–3.33 to –0.97)≥Median 0.964 (0.955-0.983)
6773/49 435 (13.7)<Median Reference
Dose-response analysis
CETP score quartile
3371/25 925 (13.0) 7.12 (5.47- 8.77) –2.14 (–4.20 to –0.08)–3.29 (–5.52 to –1.06)4 0.934 (0.889-0.979)
3459/26 048 (13.3) 4.98 (3.39-6.57) –1.38 (–3.52 to 0.75)–2.32 (–4.27 to –0.37)3 0.953 (0.910-0.998)
3415/25 011 (13.7) 2.37 (1.14-3.60) –0.69 (–2.65 to 1.27)–0.95 (–3.09 to –1.19)2 0.985 (0.929-1.041)
3576/25 853 (13.8)1 Reference
Association of genetic scores with major cardiovascular eventsB
0.7 2.01.0
OR (95% CI)
Genetic Score
OR (95% CI) per 10-mg/dL
Lower LDL−C
CETP 0.843 (0.788-0.901)
HMGCR 0.834 (0.775-0.896)
PCSK9 0.824 (0.774-0.876)
NPC1L1 0.839 (0.773-0.911)
Association of genetic scores with major cardiovascular eventsC
0.7 2.01.0
OR (95% CI)
Genetic Score
OR (95% CI) per 10-mg/dL
Lower apoB
CETP 0.781 (0.708-0.861)
HMGCR 0.794 (0.725-0.871)
PCSK9 0.787 (0.729-0.849)
NPC1L1 0.786 (0.703-0.879)
All information derived from the individual-participant data. A total of 102 837
participants who experienced a total of 13 821 first major cardiovascular events
were included in the analysis. Among all participants, median cholesteryl ester
transfer protein (CETP) genetic score was 34.8 (interquartile range [IQR],
28.3-41.1; range, 0-54.3). For participants in the group with CETP scores below
themedian, median CETP score was 28.2 (IQR, 23.3-32.0; range, 0-34.7).
For participants in the group with CETP scores equal to or above themedian,
median CETP score was 41.1 (IQR, 37.9-44.8; range, 34.8-54.3). Higher scores
indicate a greater number of high-density lipoprotein cholesterol
(HDL-C)–raising alleles (weighted by the effect of each allele on HDL-C level)
and is analogous to treatment with increasingly potent CETP inhibitors. Lipid
and lipoprotein values are presented in mg/dL (to convert HDL-C and
low-density lipoprotein cholesterol [LDL-C] values to mmol/L, multiply by
0.0259) as the difference in mean value for each group compared with the
reference group, with 95% confidence intervals. Associations with major
cardiovascular events were calculated using an inverse variance–weighted
fixed-effects meta-analysis of the study-specific estimates of effect. In panels B
and C, the association between the CETP score and risk of major cardiovascular
events is compared with the association between the risk of major
cardiovascular events and genetic scores consisting of variants in the
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) gene (encodes the target
of statins), proprotein convertase subtilisin/kexin type 9 (PCSK9) gene
(encodes target of PCSK9 inhibitors), and Niemann-Pick C1-Like 1 intracellular
cholesterol transporter 1 (NPC1L1) gene (encodes target of ezetimibe). All
associations between the genetic scores and risk of major cardiovascular events
are standardized per 10-mg/dL lower level of LDL-C (panel B) or 10-mg/dL
lower level of apolipoprotein B (apoB) (panel C) andmeasured in the overall
sample of studies that contributed individual-participant data. Data markers
indicate point estimates of effect and are of equal size because the analysis
compared approximately equal-sized groups divided by themedian CETP score
value or quartiles of the CETP score (panel A). OR indicates odds ratio.
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the risk ofmajor cardiovascular events comparedwith partici-
pants in the group with higher HMGCR scores alone (Table 2
and Figure 3A). A synthesis of the evidence from all published
CETP inhibitor randomized trials demonstrated a similar at-
tenuation in apoB reduction resulting in a discordance be-
tween the observed reduction in LDL-C and apoB levels when
any CETP inhibitor was added to treatment with a statin, re-
gardlessofwhetherLDL-Cwasmeasuredusing theFriedewald
equation or the β-quantification method (eTable 9 in the
Supplement).7-11,23,24Theobservedattenuation inapoB reduc-
tion with combination therapy in these randomized trials re-
capitulates the genetic associationwith combinedexposure to
CETP andHMGCR variants observed in this study.
To further clarify the associationof combinedexposure to
CETP andHMGCRvariantswith both lipoprotein changes and
the risk of cardiovascular events, a stratified analysiswasper-
formed. Among participants with HMGCR scores below the
median (analogous toCETP inhibitormonotherapy), theCETP
score was associated with 4.81-mg/dL higher mean HDL-C
level, 2.21-mg/dL lowermeanLDL-C,aconcordant2.06-mg/dL
lower mean apoB, and a corresponding lower risk of cardio-
vascular events (OR, 0.946 [95% CI, 0.921-0.972]; P < .001).
By contrast, among participants withHMGCR scores equal to
or above themedian (analogous to combination therapywith
a CETP inhibitor added to a statin), the CETP score was asso-
ciatedwitha similar4.42-mg/dLhighermeanHDL-C level and
2.08-mg/dL lower mean LDL-C but with an attenuated
0.59-mg/dL lowermean apoB and no significant reduction in
cardiovascularevents (OR,0.985[95%CI,0.959-1.012];P = .26)
(Figure 3B). The associationwithmajor cardiovascular events
in this group was less than expected for the observed change
inLDL-C level (P = .04) and insteadwasproportional to the at-
tenuated change in apoB.
The genome-wide association study identified 21 indepen-
dently inheritedvariantsassociatedwithdiscordantchangesbe-
tween levels of LDL-C and apoB similar in magnitude to that
seen when CETP variants are combined withHMGCR variants
(eTable10intheSupplement). Inanalyses involvingupto60801
participants with coronary artery disease and 123504 control
participants fromtheCARDIoGRAMplusC4DConsortium,age-
netic score consistingof these21 variantswas associatedwith a
significantly less thanexpected riskofCHDper 10-mg/dL lower
LDL-C level (OR, 0.916 [95%CI, 0.890-0.943] vs0.831 [95%CI,
0.816-0.847];P = 2.9 × 10−8fordifference),butaverysimilarrisk
of CHD per 10-mg/dL lower apoB (OR, 0.772 [95% CI, 0.701-
0.844] vs 0.788 [95% CI, 0.769-0.807]; P = .79 for difference),
as compared with an LDL-C genetic score consisting of 36
geneticvariantsassociatedwithLDL-Catgenome-wide levelof
significance and concordant changes in apoB level (Figure 4;
eTables 11 and 12 in the Supplement).
Discussion
Genetic variants in the target of CETP inhibitors were associ-
ated with higher HDL-C levels and concordant reductions in
levelsofLDL-CandapoBandacorresponding lower riskof car-
diovascular events that was similar inmagnitude to the asso-
ciation between genetic variants in the target of other LDL-
lowering therapies and the risk of cardiovascular events per
Table 2. Association Between CETP andHMGCRGenetic ScoresWith Biomarkers and Cardiovascular Events Among 102837 Participants
From 14 Cohort or Case-Control Studiesa
Overall Study
Sample
(N = 102 837)
Mean (95% CI)
Both Scores <Median
(n = 25 693)
CETP Score ≥Median
(n = 27 031)
HMGCR Score ≥Median
(n = 23 854)
Both Scores ≥Median
(n = 26 259)
No. of cases (%) 13 821 (13.4) 3622 (14.1) 3631 (13.4) 3145 (13.2) 3423 (13.0)
OR (95% CI) for major
cardiovascular events
Reference 0.952
(0.910 to 0.995)
0.929
(0.880 to 0.981)
0.920
(0.869 to 0.976)
Lipid levels, mg/dL
HDL-C (n = 72 411)b,c 49.3
(49.0 to 49.6)
53.9
(53.6 to 54.2)
50.2
(49.8 to 50.6)
54.7
(54.4 to 55.0)
LDL-C (n = 56 754)b,c 132.4
(131.7 to 133.2)
130.3
(129.5 to 131.0)
129.2
(128.4 to 129.9)
127.1
(126.3 to 127.9)
apoB (n = 18 312)b,c 103.4
(102.5 to 104.3)
101.5
(100.6 to 102.3)
100.7
(99.8 to 101.6)
100.1
(99.2 to 100.9)
CETP activity, SMD (n = 6436)b,d Reference −0.319
(0.462 to −0.176)
−0.008
(−0.026 to 010)
−0.323
(−0.451 to −0.196)
Genetic scores, median (IQR)
[range]
CETP 34.8 (28.3 to 41.1)
[0 to 54.3]
28.4 (23.3 to 31.8)
[0 to 34.7]
41.4 (37.9 to 45.1)
[34.8 to 54.3]
28.1 (23.1 to 31.8)
[0 to 34.7]
40.9 (37.8 to 44.7)
[34.8 to 54.3]
HMGCR 16.8 (14.6 to 20.8)
[4.1 to 22.4]
14.6 (12.2 to 16.2)
[4.1 to 16.7]
14.6 (11.8 to 16.2)
[4.1 to 16.7]
20.8 (19.1 to 22.3)
[16.8 to 22.4]
20.8 (19.1 to 22.4)
[16.8 to 22.4]
Abbreviations: apoB, apolipoprotein B; CETP, cholesteryl ester transfer protein;
HMGCR, HMG-CoA reductase; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; SMD, standardized
mean difference.
SI conversion factors: To convert HDL-C and LDL-C values to mmol/L, multiply
by 0.0259.
a Values are derived from individual-participant data.
bNo. in parentheses indicates participants with biomarker data.
c Means and 95% confidence intervals defined by different combinations of
genetic scores were derived from a fixed-effects inverse variance–weighted
meta-analysis of studies that reported these values.
dBecause CETP activity was measured on different scales in the studies that
measured CETP activity, values were transformed to unit-less standardized
mean differences.
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unit change in level ofLDL-C (andapoB).However,whencom-
binedwith variants in the target of statins, variants in the tar-
get of CETP inhibitorswere associatedwithdiscordant reduc-
tions in LDL-C and apoB level and a corresponding reduction
in cardiovascular events that was proportional to the attenu-
ated reduction inapoBbut significantly less thanexpectedper
unit change in LDL-C.
Thesemendelian randomizationanalyses suggest that the
causal effect of CETP inhibition on the risk of cardiovascular
events appears to be determined by changes in the concen-
trationof apoB-containing lipoproteins rather thanchanges in
LDL-C or HDL-C level. In external validation analyses, a ge-
netic score consisting of 21 variants with similar naturally oc-
curring discordance between changes in levels of LDL-C and
apoB also was associated with the risk of cardiovascular dis-
easeproportional to change in level of apoB rather thanLDL-C.
Together, these findings suggestmoregenerally that thecausal
effect of LDL on the risk of cardiovascular disease appears to
be determined by the concentration of circulating apoB-
containing lipoprotein particles rather than by the total cho-
lesterol mass carried by those particles (as estimated by the
plasma LDL-C level).
Thesemendelianrandomizationresultsareconsistentwith
the results of several previous discordant effects analyses of
LDL-CandapoB, suggesting that the riskof cardiovasculardis-
ease ismore closely related to apoB level than to LDL-C level.
Undermost circumstances, LDL-C and apoB levels are highly
correlated and therefore provide similar information about
cardiovascular risk. It is only when they become discordant
that the differential effects of LDL-C and apoB on the risk of
Figure 3. Separate and Combined Effects of the CETP andHMGCR Scores on Risk ofMajor Cardiovascular Events Among 102837 Participants
From 14 Cohort or Case-Control Studies
2 × 2 Factorial analysis of CETP and HMGCR genetic scoresA
0.7 2.01.0
OR (95% CI)
Major Cardiovascular
Events, No. of Cases/
No. of Participants (%)
Change, Mean (95% CI), mg/dL 
HDL−C LDL−C apoBGroup OR (95% CI)
Both scores
≥median 3423/26 259 (13.0) 5.40 (4.16-6.64) –3.33 (–5.19 to –1.46)–5.29 (–7.29 to –3.29) 0.920 (0.869-0.976)
Both scores
<median 3622/25 693 (14.1) Reference
HMGCR score
≥median 3145/23 854 (13.2) 0.83 (0.11-1.56) –2.74 (–4.31 to –1.07)–3.27 (–5.08 to –1.46) 0.929 (0.880-0.981)
CETP score
≥median 3631/27 031 (13.4) 4.64 (3.44-5.83) –1.93 (–3.27 to –0.57)–2.16 (–3.69 to –0.63) 0.952 (0.910-0.995)
Effect of CETP genetic score, stratified by HMGCR scoreB
0.7 2.01.0
OR (95% CI)
Major Cardiovascular
Events, No. of Cases/
No. of Participants (%)
Change, Mean (95% CI), mg/dL 
HDL−C LDL−C apoBGroup OR (95% CI)
HMGCR score < median
CETP score
≥median 3631/27 031 (13.4) 4.64 (3.44-5.83) –1.93 (–3.27 to –0.57)–2.16 (–3.69 to –0.63) 0.946 (0.921-0.972)
CETP score
<median 3622/25 693 (14.1) Reference
HMGCR score ≥ median
CETP score
≥median 3423/26 259 (13.0) 4.57 (3.26-5.88) –0.59 (–1.81 to 0.64)–2.02 (–3.76 to –0.28) 0.985 (0.959-1.012)
CETP score
<median 3145/23 854 (13.2) Reference
All information derived from the individual-participant data. A total of
102 837 participants who experienced a total of 13 821 first major cardiovascular
events were included in the analysis. Among all participants, the median
cholesteryl ester transfer protein (CETP) genetic score was 34.8
(interquartile range [IQR], 28.3-41.1; range, 0-54.3). Themedian CETP and
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) score, IQR, and range of
values for each group is presented in Table 2. Lipid and lipoprotein values are
presented in mg/dL (to convert high-density lipoprotein cholesterol [HDL-C]
and low-density lipoprotein cholesterol [LDL-C] values to mmol/L, multiply by
0.0259) as the difference in mean value for each group compared with the
reference group, with 95% confidence intervals. Associations with major
cardiovascular events were calculated using an inverse variance–weighted
fixed-effects meta-analysis of the study-specific estimates of effect. In panel B,
the study population was first divided into 2 groups based on whether the
HMGCR score was below or equal to or greater than themedian value. The
association between the CETP score and the risk of major cardiovascular events
was then estimatedmodeling the CETP score as a continuous variable scaled to
the lipid effects in the dichotomous score analysis. There was evidence for
effect modification of theHMGCR score on the association between the CETP
genetic score and the risk of major cardiovascular events (P = .04). Data
markers indicate point estimates of effect and are of equal size because the
analysis compared approximately equal-sized groups divided into a factorial
analysis (panel A) or themedianHMGCR score value (panel B). Error bars
represent 95% confidence intervals. apoB indicates apolipoprotein B;
OR, odds ratio.
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atherosclerosis canbe evaluated. The results of thesemende-
lian randomizationanalysesprovidenaturally randomizedge-
neticevidencetosupport thepreviousdiscordantanalysis find-
ings that the likelihood of an apoB-containing lipoprotein
particle entering into and being trapped within the subinti-
mal spaceof the arterialwall ismore closely related to the con-
centrationof circulating apoB-containing lipoproteins than to
the variable mass of cholesterol within them.25-27
The resultsof thecurrentmendelian randomizationanaly-
ses suggest that theclinicalbenefitof loweringLDL-C levelmay
bedeterminedby thecorrespondingabsolute reduction incon-
centration of apoB-containing particles. Therefore, the clini-
calbenefitof loweringLDL-CmaydependonhowLDL-C is low-
ered.Therapiessuchasstatins,ezetimibe,andPCSK9inhibitors
that lowerLDL-C levelby reducingcirculatingLDLparticlecon-
centration through up-regulation of LDL receptors should re-
duce the riskof cardiovascular eventsproportionally to theab-
solute reduction in either LDL-C level or the concordant
absolute reduction in apoB. By contrast, therapies that lower
LDL-C levelwithoutproportionally reducingapoB level, for ex-
ample by altering the lipid content of apoB-containing lipo-
proteins without necessarily decreasing the concentration of
those particles,mayhave an attenuatedbenefit on cardiovas-
cular disease risk reduction that is proportional to the change
in apoB level but less than expectedper unit change in LDL-C.
This finding may help to reconcile the causal effect
of LDL on cardiovascular disease with the results of the
ACCELERATE trial by providing a possible explanation for
how treatment with evacetrapib can lower LDL-C level with-
out reducing the risk of cardiovascular events. Adding a
CETP inhibitor to a statin leads to an attenuated reduction in
apoB-containing lipoproteins compared with treatment with
a CETP inhibitor alone, thus resulting in a discordance
between the observed changes in levels of LDL-C and apoB.
In the ACCELERATE trial, treatment with evacetrapib plus a
statin reduced LDL-C level by 37% compared with treatment
with a statin plus placebo, but only reduced plasma apoB
level by 15%, less than half the expected apoB reduction
with evacetrapib monotherapy.11 After 2 years of treatment,
the corresponding 29-mg/dL absolute reduction in LDL-C
would be expected to reduce the risk of major cardiovascular
events by approximately 13% to 19%, which is much greater
than the 5% to 8% reduction in risk that would be expected
from the attenuated 12-mg/dL absolute reduction in
apoB.4,28 This attenuated expected effect size based on the
attenuated change in apoB falls well within the confidence
bounds of the effect reported in the ACCELERATE trial (haz-
ard ratio, 0.97 [95% CI, 0.85-1.10] for the composite outcome
of cardiovascular death, myocardial infarction, or stroke).11
Similarly, the recently completed andmuch larger 30000
person REVEAL (Randomized Evaluation of the Effects of
Anacetrapib Through Lipid Modification) trial reported that
treatment with anacetrapib plus a statin significantly re-
ducedtheriskofcardiovascularevents,but furtherdetailshave
not yet been reported.29 This trial had a median follow-up of
4 years, which should be long enough to observe the full ef-
fect of theCETP inhibitor–induced lipoprotein changes on the
riskof cardiovascular events.28The results of the currentmen-
delian randomization analyses would suggest that treatment
with anacetrapib plus a statin should reduce the risk of car-
diovascular eventsproportional to theabsolutechange inapoB
level, whichmay be less than the expected risk reduction per
unit lower LDL-C level depending on the level of discordance
between the change in LDL-C and apoB that occurs when an-
acetrapib is added to treatment with atorvastatin.
Furthermore, the results of these mendelian randomiza-
tion analyses also suggest that treatment with a CETP inhibi-
tor as monotherapy may have the potential to effectively re-
duce the risk of cardiovascular events. Both genetic and
therapeutic inhibitionof CETP leads to quantitatively concor-
dant changes inLDL-CandapoB levelswhenconsidered in the
absence of HMG-CoA reductase inhibition. Therefore, treat-
mentwith a potent CETP inhibitorwithout a statin could lead
to large concordant absolute reductions in both LDL-C and
apoB, which could in turn lead to large relative reductions in
cardiovascular events. Future cardiovascular outcomes trials
evaluating CETP inhibitor therapy in statin-intolerant pa-
tients could test this hypothesis directly.
Figure 4. Association of Genetic VariantsWith Naturally Occurring Discordance Between Changes in Concentrations of LDL-C and apoB and the Risk
of CHDAmong CARDIoGRAMplusC4D Consortium Participants
0.7 2.01.0
OR (95% CI)
Effect per 10-mg/dL lower LDL-C
OR (95% CI) MR-Egger OR (95% CI)
P Value for
Difference
Discordant variants score (21 variants) 0.916 (0.890-0.943) 0.909 (0.826-0.992)
LDL-C score (36 variants) 0.831 (0.816-0.847) 0.839 (0.811-0.867)
Effect per 10-mg/dL lower apoB
Discordant variants score (21 variants) 0.772 (0.701-0.844) 0.747 (0.585-0.967)
LDL-C score (36 variants) 0.788 (0.769-0.807) 0.785 (0.751-0.821)
2.9 x 10–8
.68
Analyses are based on summary data from up to 62 240 participants
with coronary heart disease (CHD) and 127 299 control participants from
the Coronary Artery DIsease GenomeWide Replication andMeta-analysis
plus the Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) Consortium.
Effect sizes are standardized per 10-mg/dL lower level of low-density
lipoprotein cholesterol (LDL-C) or 10-mg/dL lower level of apolipoprotein B
(apoB). MR-Egger regression estimates are presented for sensitivity
analyses. Data markers indicate point estimates of effect; error bars,
95% confidence intervals.
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The current mendelian randomization analyses recon-
cile the conflicting results between previous mendelian
randomization studies and the CETP inhibitor randomized
trials. Prior mendelian randomization studies have reported
that some CETP variants are weakly associated with lower
CETP activity, higher HDL-C level, slightly lower LDL-C, and
a marginally lower risk of cardiovascular disease.30,31 These
studies helped to establish CETP as a “genetically validated”
drug target. The failure of CETP inhibitors to reduce the risk
of cardiovascular events in 3 large randomized outcome
trials therefore challenges the utility of using mendelian
randomization studies to inform drug discovery and devel-
opment programs. However, the prior mendelian random-
ization studies did not evaluate the combined effect of
CETP and HMGCR variants and therefore could not have
detected the attenuation in apoB reduction that occurs
when CETP inhibition is combined with HMG-CoA inhibi-
tion. To provide relevant information to inform drug discov-
ery and development, future mendelian randomization
studies should be designed to explicitly evaluate the effect
of variants in therapeutic targets the way therapies directed
against those targets are likely to be used in clinical practice,
including in combination with relevant required back-
ground therapy.17,18
This study has several limitations. First, the results of
a mendelian randomization study do not establish causality.
Second, mendelian randomization studies cannot evaluate
the impact of acutely raising HDL-C to very high, supra-
physiologic levelswithaCETP inhibitor. It is possible that very
high levels of HDL-C, reflected by a predominance of large,
cholesterol-richparticles,maybedeleteriousandthereforemay
offset the potential clinical benefit of lowering levels of apoB-
containing lipoprotein particles with a CETP inhibitor.
Third, treatment with the combination of a CETP inhibi-
tor andastatinhas resulted ina small increase in systolicblood
pressure in each of the 3 large cardiovascular outcome trials
completedtodate.7,11,23This increasedbloodpressuremayhave
offset some of the potential benefit of the already attenuated
apoB-loweringeffectof combination therapyon the riskof car-
diovascular events. Fourth, CETP inhibition might increase
cardiovascular risk through some other as-yet unknown
mechanism that counterbalances any benefit from LDL low-
ering. Fifth, the mechanism by which changes in LDL-C and
apoB levels becomediscordantwhenCETP inhibition is com-
binedwithHMG-CoAreductase inhibition isunclear, but could
be related to the redistributionof cholesterolbetweenHDLand
LDL particles.32 Regardless of the mechanism, this effect has
been observed in all randomized trials evaluating combined
treatment with a CETP inhibitor and a statin and recapitu-
lates the genetic effect observed in this study.
Conclusions
Combined exposure to variants in the genes that encode the
targets of CETP inhibitors and statinswas associatedwithdis-
cordant reductions inLDL-CandapoB levels andacorrespond-
ing risk of cardiovascular events that was proportional to the
attenuated reduction in apoB but significantly less than ex-
pected per unit change in LDL-C. The clinical benefit of low-
ering LDL-C levels may therefore depend on the correspond-
ingabsolute reduction inapoB-containing lipoproteinparticles.
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